SCHEMBL6452695

SCHEMBL6452695

O=Cc1[c]c(-c2ccccc2)no1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
NPC1 O15118 4/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
NTSR1 P30989 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
GSR P00390 1/20 0.38
IP6K1 Q92551 1/20 0.36
NR1H4 Q96RI1 1/20 0.34
RAB9A P51151 5/20 0.33
CYP2A6 P11509 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PTPN1 P18031 1/20 0.33
BRD4 O60885 2/20 0.32
NOTUM Q6P988 1/20 0.32
BRD2 P25440 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092874 0.74 NR1H4 (0.42) ALDH1A1NPC1MEN1KMT2AKDM4E
SCHEMBL314833 0.72 BRD4 (0.47) NPC1MEN1KMT2ANR1H4RAB9A
SCHEMBL7377440 0.68 ABCC4 (0.42) ALDH1A1NPC1MEN1KMT2AKDM4E
SCHEMBL16863686 0.68 PTGS1 (0.42) ALDH1A1NPC1MEN1KMT2AKDM4E
SCHEMBL3645802 0.68 S1PR1 (0.40) MEN1KMT2APOLBNR1H4L3MBTL1
SCHEMBL6452700 0.68 NOTUM (0.43) ALDH1A1NPC1GPR55NR1H4RAB9A
SCHEMBL436193 0.66 CYP1A2 (0.47) ALDH1A1NPC1MEN1KMT2AKDM4E
SCHEMBL3150963 0.66 MEN1 (0.38) ALDH1A1NPC1MEN1KMT2APOLB
SCHEMBL1312698 0.61 RAB9A (0.55) ALDH1A1NPC1MEN1KMT2ARAB9A
SCHEMBL14562709 0.61 NR1H4 (0.57) NPC1POLBNR1H4RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005009354-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY PHARMACIA CORPORATION (US) 2005-02-03 WO disclosed